A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-31.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 101st largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 62nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 129th largest by enrollment of the 141 interventional ones that give a count, is one of 37 that started in 2012, is one of 85 in phase 3, and was the 140th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single arm, multicenter long-term extension study will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who have completed the 104-week WA19926 core study. Eligible participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.
Drug: Tocilizumab
Tocilizumab 8 mg/kg administered intravenously.
Also known as: RoActemra®, Actemra®
Percentage of Participants With Any Adverse Event (AE)
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any AE that is fatal; life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect in a neonate/infant or significant medical event in the Investigator's judgment. AE of special interest (AESI) includes serious and/or medically significant infectious; myocardial infarction(MI) / acute coronary syndrome (ACS); gastrointestinal (GI) perforation; anaphylaxis / hypersensitivity reactions; demyelinating disorders; stroke; serious and/or medically significant bleeding events; serious and/or medically significant hepatic events; malignancies malignant.
Time frame: Up to 160 weeks
Percentage of Participants With at Least One Clinical Remission Period
Clinical remission: Disease Activity Score Based on 28-joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) less than (\<)2.6 and/or Simplified Disease Activity Index (SDAI) less than or equal to (≤)3.3 for a period of at least two consecutive assessment visits (every 12 weeks) over the extension study period. DAS28-ESR was calculated using Swollen Joint Count Based on 28 Joints (SJC28), Tender Joint Count Based on 28 Joints (TJC28), ESR (mm/hour) and patient's global assessment of disease activity (100-millimeter (mm) horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity. DAS28-ESR scores range from 0-10, with higher scores corresponding to greater disease activity. SDAI was calculated using SJC28, TJC28, C-reactive protein (CRP) (milligrams per liter (mg/L)), the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0-86, where lower scores indicate less disease activity.
Time frame: Up to approximately 148 weeks
Percentage of Participants With at Least One Drug-Free Period
Drug-free remission period was defined as clinical remission for at least 2 consecutive assessment visits (every 12 weeks) AND without tocilizumab administration during this clinical remission period.
Time frame: Up to approximately 148 weeks
Cumulative Time of Remission Per Participant Over the Extension Study Period
Clinical remission was defined as DAS28-ESR \<2.6 and/or SDAI ≤3.3 for a period of at least two consecutive assessment visits (every 12 weeks) over the extension study period. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity. SDAI scores range from 0 to 86, where lower scores indicate less disease activity.
Time frame: Up to approximately 148 weeks
Percentage of Participants With at Least 1 Rheumatoid Arthritis (RA) Flare
An RA flare was defined as an increase in DAS28-ESR from the previous available visits of \>1.2, or \>0.6 if current DAS28-ESR ≥3.2. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.
Time frame: Up to approximately 148 weeks
Time to RA Flare Following Remission or Drug-Free Remission
Time to RA flare was defined as period of clinical remission or drug-free remission followed by flare of DAS28-ESR (increase in DAS28-ESR from the previous available visits of \>1.2, or \>0.6 if current DAS28-ESR ≥3.2). In the case of several remission periods for the same participant, the largest period was used.
Time frame: Up to approximately 148 weeks
Change From Day 1 in DAS28-ESR Scores Over Time
DAS28-ESR was calculated using Swollen Joint Count Based on 28 Joints (SJC28), Tender Joint Count Based on 28 Joints (TJC28), ESR (mm/hour) and patient's global assessment of disease activity (100-millimeter (mm) horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Change From Day 1 in Simplified Disease Activity Index (SDAI) Scores Over Time
SDAI was calculated using SJC28, TJC28, C-reactive protein (CRP) (milligrams per liter (mg/L)), and the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0 to 86, where lower scores indicate less disease activity.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Change From Day 1 in Tender Joint Count Based on 28 Joints (TJC28) Over Time
The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 tender joints. Higher scores correspond to greater disease activity.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Change From Day 1 in Swollen Joint Count Based on 28 Joints (SJC28) Over Time
The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 swollen joints. Higher scores correspond to greater disease activity.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Erythrocyte Sedimentation Rate (ESR) Over Time
ESR is an direct measure of how much inflammation is in the body. The normal range is 0-22 mm/hour for men and 0-29 mm/hour for women. Higher scores correspond to greater disease activity.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
C-reactive Protein (CRP) Level
C-reactive protein (CRP) is a blood test marker for inflammation in the body. Normal CRP levels are below 5 milligrams per liter (mg/L). Higher scores correspond to greater disease activity.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Participants' Global Assessment of Pain (VAS) Score
The participants' global assessment of pain (VAS) was assessed using a 100-mm horizontal VAS with 0=no pain to 100=maximum pain.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Participants' Global Assessment of Disease Activity (VAS) Score
The participants' global assessment of disease activity (VAS) was assessed using a 100-mm horizontal VAS with 0=no disease activity to 100=maximum disease.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Physicians' Global Assessment of Disease Activity (VAS) Score
The physicians' global assessment of disease activity (VAS) was assessed using a 100-mm horizontal VAS with 0=no disease activity to 100=maximum disease.
Time frame: Day 1 and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
Percentage of Participants With Health Assessment Questionnaire Disability Index (HAQ-DI) Remission
HAQ-DI remission was defined as HAQ-DI score \<0.5. HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline and Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128 140
Percentage of Participants With Clinically Meaningful Improvement From Baseline in HAQ-DI
Clinically meaningful improvement was defined as an improvement in HAQ-DI score of ≥0.22. HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, 116, 128, 140
| Milestone | Tocilizumab |
|---|---|
| Started | 15 |
| Completed | 12 |
| Not completed | 3 |
| Withdrew: Investigator decision | 1 |
| Withdrew: Moved to another city | 1 |
| Withdrew: Insufficient treatment response | 1 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is any AE that is fatal; life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect in a neonate/infant or significant medical event in the Investigator's judgment. AE of special interest (AESI) includes serious and/or medically significant infectious; myocardial infarction(MI) / acute coronary syndrome (ACS); gastrointestinal (GI) perforation; anaphylaxis / hypersensitivity reactions; demyelinating disorders; stroke; serious and/or medically significant bleeding events; serious and/or medically significant hepatic events; malignancies malignant.
| percentage of participants | Tocilizumab |
|---|---|
| AE | 93.3 |
| SAE | 6.7 |
| Non-serious AE | 93.3 |
| Tocilizumab-related AE | 80.0 |
| Tocilizumab-related SAE | 0 |
| Tocilizumab-related non-SAE | 80.0 |
| AESI | 20.0 |
| Tocilizumab-related AESI | 20.0 |
| AE leading to dose modification | 33.3 |
| AE leading to Tocilizumab discontinuation | 6.7 |
| AE leading to death | 0 |
Clinical remission: Disease Activity Score Based on 28-joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) less than (\<)2.6 and/or Simplified Disease Activity Index (SDAI) less than or equal to (≤)3.3 for a period of at least two consecutive assessment visits (every 12 weeks) over the extension study period. DAS28-ESR was calculated using Swollen Joint Count Based on 28 Joints (SJC28), Tender Joint Count Based on 28 Joints (TJC28), ESR (mm/hour) and patient's global assessment of disease activity (100-millimeter (mm) horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity. DAS28-ESR scores range from 0-10, with higher scores corresponding to greater disease activity. SDAI was calculated using SJC28, TJC28, C-reactive protein (CRP) (milligrams per liter (mg/L)), the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0-86, where lower scores indicate less disease activity.
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With at Least One Clinical Remission Period | 100.0 |
Drug-free remission period was defined as clinical remission for at least 2 consecutive assessment visits (every 12 weeks) AND without tocilizumab administration during this clinical remission period.
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With at Least One Drug-Free Period | 13.3 |
Clinical remission was defined as DAS28-ESR \<2.6 and/or SDAI ≤3.3 for a period of at least two consecutive assessment visits (every 12 weeks) over the extension study period. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity. SDAI scores range from 0 to 86, where lower scores indicate less disease activity.
| days | Tocilizumab |
|---|---|
| Cumulative Time of Remission Per Participant Over the Extension Study Period | 598.00 (179.0 to 1,072.0) |
An RA flare was defined as an increase in DAS28-ESR from the previous available visits of \>1.2, or \>0.6 if current DAS28-ESR ≥3.2. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With at Least 1 Rheumatoid Arthritis (RA) Flare | 40.0 |
Time to RA flare was defined as period of clinical remission or drug-free remission followed by flare of DAS28-ESR (increase in DAS28-ESR from the previous available visits of \>1.2, or \>0.6 if current DAS28-ESR ≥3.2). In the case of several remission periods for the same participant, the largest period was used.
| days | Tocilizumab |
|---|---|
| Time to RA Flare Following Remission or Drug-Free Remission | 289.0 (179.0 to 739.0) |
DAS28-ESR was calculated using Swollen Joint Count Based on 28 Joints (SJC28), Tender Joint Count Based on 28 Joints (TJC28), ESR (mm/hour) and patient's global assessment of disease activity (100-millimeter (mm) horizontal visual analog scale with 0=no disease activity to 100=maximum disease activity. DAS28-ESR scores range from 0 to 10, with higher scores corresponding to greater disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Day 1 (n = 14) | 2.09 ± 1.12 |
| Change at Week 12 (n = 10) | -0.43 ± 0.96 |
| Change at Week 24 (n = 13) | -0.65 ± 1.86 |
| Change at Week 36 (n = 11) | -0.03 ± 1.42 |
| Change at Week 48 (n = 13) | -0.58 ± 1.46 |
| Change at Week 56 (n = 11) | -1.02 ± 1.50 |
| Change at Week 68 (n = 11) | -1.39 ± 1.31 |
| Change at Week 80 (n = 10) | -0.83 ± 1.33 |
| Change at Week 92 (n = 10) | -0.69 ± 1.50 |
| Change at Week 104 (n = 10) | -0.94 ± 1.44 |
| Change at Week 116 (n = 6) | -1.15 ± 1.37 |
| Change at Week 128 (n = 2) | 0.40 ± 1.70 |
| Change at Week 140 (n = 1) | 0.10 ± NA |
SDAI was calculated using SJC28, TJC28, C-reactive protein (CRP) (milligrams per liter (mg/L)), and the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0 to 86, where lower scores indicate less disease activity.
| units on a scale | Tocilizumab |
|---|---|
| Day 1 (n = 6) | 4.40 ± 3.67 |
| Change at Week 12 (n = 6) | -1.70 ± 3.43 |
| Change at Week 24 (n = 4 | 2.68 ± 17.12 |
| Change at Week 36 (n = 0) | NA ± NA |
| Change at Week 48 (n = 3) | -3.70 ± 3.21 |
| Change at Week 56 (n = 3) | -2.90 ± 1.64 |
| Change at Week 68 (n = 2) | -7.30 ± 3.54 |
| Change at Week 80 (n = 3) | -3.37 ± 3.42 |
| Change at Week 92 (n = 4) | -2.05 ± 5.11 |
| Change at Week 104 (n = 2) | -6.10 ± 0.14 |
| Change at Week 116 (n = 3) | -4.77 ± 2.46 |
| Change at Week 128 (n = 0) | NA ± NA |
| Change at Week 140 (n = 1) | -0.90 ± NA |
The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28 tender joints. Higher scores correspond to greater disease activity.
| tender joints | Tocilizumab |
|---|---|
| Day 1 (n = 15) | 2.07 ± 5.62 |
| Change at Week 12 (n = 15) | -0.87 ± 6.58 |
| Change at Week 24 (n = 14) | 0.29 ± 9.22 |
| Change at Week 36 (n = 14) | 1.00 ± 8.68 |
| Change at Week 48 (n = 14) | 1.07 ± 9.24 |
| Change at Week 56 (n = 13) | -1.77 ± 6.26 |
| Change at Week 68 (n = 12) | -1.42 ± 5.92 |
| Change at Week 80 (n = 11) | -2.45 ± 6.67 |
| Change at Week 92 (n = 12) | -0.67 ± 3.75 |
| Change at Week 104 (n = 11) | -1.82 ± 7.05 |
| Change at Week 116 (n = 6) | -1.00 ± 0.89 |
| Change at Week 128 (n = 3) | 0.67 ± 2.08 |
| Change at Week 140 (n = 1) | -1.00 ± NA |
The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28 swollen joints. Higher scores correspond to greater disease activity.
| swollen joints | Tocilizumab |
|---|---|
| Day 1 (n = 15) | 0.33 ± 0.62 |
| Change at Week 12 (n = 15) | 0.27 ± 1.44 |
| Change at Week 24 (n = 14) | 0.50 ± 2.03 |
| Change at Week 36 (n = 14) | 1.50 ± 2.71 |
| Chnage at Week 48 (n = 14) | 0.29 ± 1.38 |
| Change at Week 56 (n = 13) | 0.46 ± 2.07 |
| Change at Week 68 (n = 12) | -0.08 ± 1.16 |
| Change at Week 80 (n = 11) | 0.09 ± 1.38 |
| Change at Week 92 (n = 12) | 0.50 ± 2.35 |
| Change at Week 104 (n = 11) | 0.55 ± 1.86 |
| Change at Week 116 (n = 6) | -0.17 ± 1.72 |
| Change at Week 128 (n = 3) | 0.00 ± 0.00 |
| Change at Week 140 (n = 1) | 0.00 ± NA |
ESR is an direct measure of how much inflammation is in the body. The normal range is 0-22 mm/hour for men and 0-29 mm/hour for women. Higher scores correspond to greater disease activity.
| mm/hour | Tocilizumab |
|---|---|
| Day 1 (n = 14) | 10.0 (1.0 to 61.0) |
| Week 12 (n = 11) | 2.00 (1.0 to 20.0) |
| Week 24 (n = 14) | 2.50 (1.0 to 24.0) |
| Week 36 (n = 12) | 2.00 (1.0 to 26.0) |
| Week 48 (n = 14) | 2.00 (1.0 to 19.0) |
| Week 56 (n = 13) | 2.00 (1.0 to 9.0) |
| Week 68 (n = 12) | 2.50 (1.0 to 13.0) |
| Week 80 (n = 11) | 3.00 (2.0 to 6.0) |
| Week 92 (n = 11) | 2.00 (1.0 to 20.0) |
| Week 104 (n = 11) | 2.00 (1.0 to 30.0) |
| Week 116 (n= 6) | 2.00 (2.0 to 15.0) |
| Week 128 (n= 3) | 3.00 (2.0 to 4.0) |
| Week 140 (n= 1) | 10.00 (10.0 to 10.0) |
C-reactive protein (CRP) is a blood test marker for inflammation in the body. Normal CRP levels are below 5 milligrams per liter (mg/L). Higher scores correspond to greater disease activity.
| mg/L | Tocilizumab |
|---|---|
| Day 1 (n = 6) | 4.70 (0.5 to 24.0) |
| Week 12 (n = 11) | 2.00 (0.3 to 10.0) |
| Week 24 (n = 11) | 2.00 (0.2 to 9.0) |
| Week 36 (n = 6) | 0.85 (0.3 to 2.0) |
| Week 48 (n = 8) | 1.30 (0.2 to 5.0) |
| Week 56 (n = 9) | 2.00 (0.2 to 21.0) |
| Week 68 (n = 7) | 2.00 (0.5 to 12.0) |
| Week 80 (n = 8) | 2.00 (0.3 to 10.7) |
| Week 92 (n = 8) | 2.00 (0.3 to 25.0) |
| Week 104 (n = 7) | 2.00 (0.3 to 22.5) |
| Week 116 (n= 4) | 2.00 (2.0 to 3.0) |
| Week 128 (n= 1) | 2.00 (2.0 to 2.0) |
| Week 140 (n= 1) | 4.00 (4.0 to 4.0) |
The participants' global assessment of pain (VAS) was assessed using a 100-mm horizontal VAS with 0=no pain to 100=maximum pain.
| units on a scale | Tocilizumab |
|---|---|
| Day 1 (n = 15) | 11.00 (0.0 to 50.0) |
| Week 12 (n = 15) | 7.00 (0.0 to 37.0) |
| Week 24 (n = 14) | 9.00 (0.0 to 75.0) |
| Week 36 (n = 14) | 10.00 (0.0 to 66.0) |
| Week 48 (n = 14) | 8.00 (0.0 to 64.0) |
| Week 56 (n = 13) | 4.00 (0.0 to 50.0) |
| Week 68 (n = 12) | 4.00 (0.0 to 25.0) |
| Week 80 (n = 11) | 19.00 (1.0 to 40.0) |
| Week 92 (n = 12) | 8.50 (0.0 to 50.0) |
| Week 104 (n = 11) | 9.00 (0.0 to 24.0) |
| Week 116 (n= 6) | 3.50 (0.0 to 20.0) |
| Week 128 (n= 3) | 3.00 (1.0 to 20.0) |
| Week 140 (n= 1) | 6.00 (6.0 to 6.0) |
The participants' global assessment of disease activity (VAS) was assessed using a 100-mm horizontal VAS with 0=no disease activity to 100=maximum disease.
| units on a scale | Tocilizumab |
|---|---|
| Day 1 (n = 15) | 13.00 (0.0 to 30.0) |
| Week 12 (n = 15) | 17.00 (0.0 to 75.0) |
| Week 24 (n = 14) | 18.50 (0.0 to 80.0) |
| Week 36 (n = 14) | 10.00 (0.0 to 68.0) |
| Week 48 (n = 14) | 7.50 (0.0 to 49.0) |
| Week 56 (n = 13) | 5.00 (0.0 to 50.0) |
| Week 68 (n = 12) | 5.00 (0.0 to 32.0) |
| Week 80 (n = 11) | 24.00 (1.0 to 70.0) |
| Week 92 (n = 12) | 10.50 (0.0 to 30.0) |
| Week 104 (n = 11) | 10.00 (0.0 to 57.0) |
| Week 116 (n= 6) | 4.00 (0.0 to 15.0) |
| Week 128 (n= 3) | 7.00 (2.0 to 10.0) |
| Week 140 (n= 1) | 15.00 (15.0 to 15.0) |
The physicians' global assessment of disease activity (VAS) was assessed using a 100-mm horizontal VAS with 0=no disease activity to 100=maximum disease.
| units on a scale | Tocilizumab |
|---|---|
| Day 1 (n = 15) | 5.00 (0.0 to 20.0) |
| Week 12 (n = 15) | 6.00 (0.0 to 21.0) |
| Week 24 (n = 13) | 1.00 (0.0 to 60.0) |
| Week 36 (n = 14) | 5.00 (0.0 to 55.0) |
| Week 48 (n = 14) | 5.00 (0.0 to 50.0) |
| Week 56 (n = 13) | 6.00 (0.0 to 60.0) |
| Week 68 (n = 12) | 4.50 (0.0 to 13.0) |
| Week 80 (n = 11) | 3.00 (0.0 to 18.0) |
| Week 92 (n = 12) | 9.0 (0.0 to 43.0) |
| Week 104 (n = 11) | 5.00 (0.0 to 40.0) |
| Week 116 (n= 6) | 5.00 (0.0 to 10.0) |
| Week 128 (n= 3) | 15.00 (1.0 to 30.0) |
| Week 140 (n= 1) | 5.00 (5.0 to 5.0) |
HAQ-DI remission was defined as HAQ-DI score \<0.5. HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline (n = 15) | 73.3 |
| Week 12 (n = 9) | 66.7 |
| Week 24 (n = 8) | 62.5 |
| Week 36 (n = 10) | 60.0 |
| Week 48 (n = 10) | 50.0 |
| Week 56 (n = 10) | 60.0 |
| Week 68 (n = 9) | 77.8 |
| Week 80 (n = 9) | 66.7 |
| Week 92 (n = 8) | 75.0 |
| Week 104 (n = 7) | 71.4 |
| Week 116 (n= 3) | 100 |
| Week 128 (n= 1) | 100 |
| Week 140 (n= 1) | 100 |
Clinically meaningful improvement was defined as an improvement in HAQ-DI score of ≥0.22. HAQ-DI is the participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| percentage of participants | Tocilizumab |
|---|---|
| Week 12 (n = 9) | 33.3 |
| Week 24 (n = 8) | 25.0 |
| Week 36 (n = 10) | 40.0 |
| Week 48 (n = 10) | 30.0 |
| Week 56 (n = 10) | 30.0 |
| Week 68 (n = 9) | 33.3 |
| Week 80 (n = 9) | 22.2 |
| Week 92 (n = 8) | 12.5 |
| Week 104 (n = 7) | 28.6 |
| Week 116 (n= 3) | 100 |
| Week 128 (n= 1) | 100 |
| Week 140 (n= 1) | 100 |
Collected over Up to 160 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 1/15 (6.7%) | 14/15 (93.3%) |
| Event | Tocilizumab |
|---|---|
| Oedema peripheralGeneral disorders | 1/15 |
| Event | Tocilizumab |
|---|---|
| BronchitisInfections and infestations | 6/15 |
| Back painMusculoskeletal and connective tissue disorders | 5/15 |
| GastroenteritisInfections and infestations | 4/15 |
| NasopharyngitisInfections and infestations | 4/15 |
| AstheniaGeneral disorders | 4/15 |
| InsomniaPsychiatric disorders | 3/15 |
| Oral herpesInfections and infestations | 2/15 |
| PharyngitisInfections and infestations | 2/15 |
| TracheitisInfections and infestations | 2/15 |
| Urinary tract infectionInfections and infestations | 2/15 |
Analysis was performed in Included population, defined as all participants who entered the study.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 54.8 ± 9.1 |
| Gender(Participants) | Tocilizumab |
|---|---|
| Female | 12 |
| Male | 3 |
The record gives a start of Apr 2012, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab